Important note: Information in this article was accurate in 1985. The state of the art may have changed since the publication date.
The Vancouver Lymphadenopathy-AIDS Study: 1. Persistent generalized lymphadenopathy.
Can Med Assoc J. 1985 Jun 1;132(11):1273-9. Unique Identifier : AIDSLINE MED/85201282 Schechter MT; Boyko WJ; Jeffries E; Willoughby B; Nitz R; Constance P
Abstract:
The Vancouver Lymphadenopathy-AIDS (acquired immune deficiency syndrome) Study is an ongoing prospective study of over 700 homosexual men attending six primary care practices in central Vancouver. A case-control study of risk factors for persistent generalized lymphadenopathy in homosexual men was conducted in five of the practices. The participants completed a questionnaire and underwent a complete physical examination at the time of enrollment and at a subsequent visit not less than 3 months later, and laboratory tests were performed after both visits. Persistent generalized lymphadenopathy was defined as the presence of lymph nodes greater than 1 cm in diameter at two or more extrainguinal sites for more than 3 months. Of the 519 patients who had completed both visits by February 1984, 126 (24%) were found to have the disease, and two controls without lymphadenopathy were frequency-matched on the basis of age and practice to each subject. More than 100 male sexual partners during one's lifetime, frequent receptive anal intercourse, a history of gonorrhea, use of illicit drugs and sexual contact in Los Angeles were identified as independent risk factors for persistent generalized lymphadenopathy. The similarity of these risk factors to those established for AIDS supports the hypothesis of a common etiology for the two diseases, and the high prevalence rate of persistent generalized lymphadenopathy further supports the hypothesis that AIDS is an uncommon response to a relatively common agent.
Keywords: Acquired Immunodeficiency Syndrome/EPIDEMIOLOGY/*ETIOLOGY Analysis of Variance British Columbia Gonorrhea/COMPLICATIONS *Homosexuality Human Immunoblastic Lymphadenopathy/EPIDEMIOLOGY/*ETIOLOGY Male Prospective Studies Questionnaires Risk *Sex Behavior Street Drugs/POISONING Support, Non-U.S. Gov't Travel JOURNAL ARTICLE
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1985. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Important note: Information in this article was accurate in 1985. The state of the art may have changed since the publication date.
